Active Ingredient History

  • Now
Evacetrapib was a drug under development by Eli Lilly & Company that inhibits cholesterylester transfer protein. CETP collects triglycerides from very low-density lipoproteins (VLDL) or low-density lipoproteins (LDL) and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), and vice versa, but primarily increasing high-density lipoprotein and lowering low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.   Wikipedia

  • SMILES: Cc1cc(C)c2N(C[C@@H]3CC[C@H](CC3)C(=O)O)CCC[C@H](N(Cc4cc(cc(c4)C(F)(F)F)C(F)(F)F)c5nnn(C)n5)c2c1
  • Mol. Mass: 638.66
  • ALogP: 7.1
  • ChEMBL Molecule:
More Chemistry
evacetrapib | ly2484595 | ly 2484595 | ly-2484595


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue